To evaluate the clinical utility of incorporating a novel heavy/light chain immunoassay (HLC) into the existing methods for the assessment of multiple myeloma (MM) patients.
Hematological malignancy multiple myeloma is characterized by the proliferation of monoclonal plasma cells in the bone marrow, which usually leads to the secretion of monoclonal intact immunoglobulins (Ig), free light chains (FLC), or both, into the serum. Consequently, the measurement of monoclonal proteins is integral to diagnosing multiple myeloma, monitoring of response to treatment, and detecting relapse (1) (2) (3) . Conventional methods rely principally on serum electrophoresis together with either urine electrophoresis for the detection of FLC M-proteins or nephelometric quantification of total Igs for intact Ig paraprotein measurement. However, these standard techniques often do not have the required sensitivity or do not correlate with the patient's clinical status (4) (5) (6) (7) .
The ability to detect monoclonal serum FLC has been substantially increased by the introduction of the serum FLC assay, improving the diagnosis, monitoring, and prognosis of a number of plasma cell dyscrasias (8, 9) . Still, a number of problems associated with the detection of monoclonal intact Igs persist. Serum Ig concentrations can change for ≥50% with fluctuations in blood volume and/or hematocrit (10). In the case of monoclonal IgGs, the serum concentration can be also influenced by altered metabolism due to recycling of IgG by the neonatal Fc receptors (11) (12) (13) . Furthermore, monoclonal proteins, in particular IgA paraproteins, may not be accurately quantified by serum protein electrophoresis (SPE) due to co-migration with other serum proteins (14, 15) . Finally, one of the major limitations of measuring total Igs is the inability to distinguish between the monoclonal component and polyclonal Ig background.
These problems can be addressed by a recently developed heavy/light chain (HLC) immunoassay. Using specific antibodies targeted to junctional epitopes of the heavy and light chains of Ig molecules, HLC immunoassay separately quantifies different light chain types of each Ig class (IgGκ, IgGλ, IgAκ, IgAλ, etc), thus providing accurate quantification of both the involved and uninvolved components of the patient's affected Ig isotype. The ratio of the monoclonal and polyclonal Igs of the same isotype (IgGκ/IgGλ, IgAκ/IgAλ) provides a sensitive measure of monoclonality, while minimizing the influence of changes in blood volume/hematocrit and the effect of IgG recycling (16, 17) .
Previous studies using this novel assay in specific, controlled patient cohorts found the HLC ratio to be useful for screening, monitoring, and risk stratification of patients with multiple myeloma, but also with other monoclonal gammopathies, such as monoclonal gammopathy of undetermined significance (MGUS) and amyloid light-chain (AL) amyloidosis (18) (19) (20) . The aim of this study was to evaluate the ability of the new assay -HLC isotype measurements -to detect monoclonal protein (ie, residual disease) in previously treated multiple myeloma patients and to determine whether these patients can benefit from adding the new assay into a routine assessment.
PatIeNtS aND MethoDS
The study included 90 unselected intact Ig multiple myeloma patients in different clinical stages (symptomatic disease) who had received at least one line of different treatment regiments (the number of patients was limited by availability of serum assays but also by the number of patients who were willing to enter the study). Written informed consent was obtained from each patient before entering the study. Patients were enrolled consecutively as they presented for routine assessment at our hospital between January 2011 and October 2013. At the time of the assessment, all patients already completed treatment regiments. The median follow-up period was 17.4 months (range 0.5-46.1 months; follow up period is defined as time elapsed from the day of the sampling until January 2015 when statistical analysis was performed 
Relationship between hLC ratio and serum FLC ratio
Abnormal HLC ratio in the presence of normal FLC ratio revealed monoclonal protein in additional 4/23 (17%) patients in complete response, 8/34 (24%) patients with very good partial response, and 3/10 (30%) patients with stable disease (Table 2) . In all patients with progressive disease, both assays were positive. HLC and FLC assays provided sometimes differing but complementary information, ie, in some patients both assays indicated the presence of monoclonal protein and in others only one of the assays did so. This was perhaps most notable in 8/23 patients who had achieved complete response (Table 2) . Nevertheless, 2 of the 5 patients in complete response but with an abnormal HLC ratio suffered a relapse during the follow up period. 
Disease variables and involved (monoclonal) hLC measurements
In order to assess whether the new assay truly reflected disease activity and provided good measurement of tumor burden (ie, residual disease), we tested the correlations between HLC measurements (involved HLC isotype values and HLC ratio) and other disease variables. Looking at the entire cohort, abnormal HLC ratio values correlated with the percentage of clonal plasma cells in the bone marrow (P = 0.002) and an abnormal serum FLC ratio (P < 0.001). Involved HLC isotype concentration above normal values correlated with serum beta-2-microglobulin values (P = 0.038), percentage of clonal plasma cells in the bone marrow (P < 0.001), and abnormal serum FLC ratio (P < 0.001).
Analyzing the data according to Ig isotype, abnormal IgGκ/ IgGλ HLC ratios (normal range 0.98-2.75) correlated with the percentage of clonal plasma cells in the bone marrow (P = 0.020), abnormal serum FLC ratio (P < 0.001), and hemoglobin concentration (P = 0.032). Monoclonal IgGκ or IgGλ isotype concentrations above the normal upper limit (for IgGκ above 9.78 g/L and for IgGλ above 5.71 g/L) correlated with serum beta-2-microglobulin concentration (P = 0.011), percentage of clonal plasma cells in the bone marrow (P = 0.007), and abnormal serum FLC ratio (P = 0.002).
Abnormal IgAκ/IgAλ ratios (normal range 0.80-2.04) correlated with abnormal serum FLC ratio (normal range 0.26-1.65; P = 0.023) and serum beta-2-microglobulin concentration (P = 0.04), while correlation with the percentage of clonal plasma cells in the bone marrow was not as strong (P = 0.08). Monoclonal IgAκ or IgAλ isotype concentrations higher than normal upper limit (for IgAκ above 2.82 g/L and for IgAλ above 1.98 g/L) correlated with serum beta-2-microglobulin concentration >3.5 mg/L (P = 0.050) and abnormal serum FLC ratio (P = 0.005).
Disease variables and uninvolved (polyclonal) hLC isotype level
Correlations regarding the suppression of the polyclonal HLC isotype pair (ie, suppression of IgGλ in a IgGκ myeloma patient), were also assessed. Suppression was defined as an istoype pair value below normal range. In the entire group, there were significant correlations between isotype pair suppression and abnormal serum FLC ratio (P < 0.001), as well as hemoglobin concentration <100 g/L (P = 0.005).
The same was found when looking at IgG group alone (abnormal serum FLC ratio, P < 0.001 and hemoglobin <100 g/L, P < 0.001), while in the IgA group there were no significant correlations between the suppressed polyclonal isotype and other tumor markers, possibly due to the small number of patients.
hLC measurements and overall survival
The aim of this study was to determine not only the ability of the new assay to detect monoclonal protein, ie, residual disease but also the clinical relevance of HLC assay measurement in multiple myeloma patients regardless of the type of treatment and time elapsed from the last course of therapy. For this purpose, Kaplan-Meier analysis was performed for OS of patients from the date of enrolment onwards. Patients were stratified according to HLC ratio values, and OS was significantly shorter in patients with abnormal HLC ratio value (median OS not reached, P < 0.001) ( Figure 1A ). When patients were stratified according to monoclonal isotype concentrations, OS was significantly shorter in patients with values above normal range (median 31.7 months vs median not reached, P = 0.002) ( Figure 1B) .
Interestingly, when patients were stratified according to the presence or absence of suppression of the uninvolved polyclonal HLC isotype pair, those with isotype suppres- sion also had significantly shorter OS (median 31 months vs median not reached, P = 0.021, Figure 2 ).
The clinical relevance of the HLC assay was even more evident when Kaplan-Meier analysis was performed in patients who achieved very good partial responses (defined as negative SPE and positive IFE) and complete response (both SPE and IFE negative). When this subgroup of patients was stratified according to HLC ratio value, OS was significantly shorter in patients with abnormal HLC ratio values than in very good partial responses/complete response patients with normal HLC ratio (median 27.2 month vs median not reached, P = 0.033) (Figure 3 ).
Prognostic significance of hLC measurements
In order to assess the prognostic significance of the new assay, Cox multivariate regression analysis was performed for the entire study population and for the group of patients who achieved very good partial response or better. An abnormal HLC ratio as well as high beta-2-microglobulin (>3.5 mg/L) concentration were independent predictors of OS for the entire cohort (risk ratio [RR] 4.7, confidence interval [CI] 0.96-23.47, P = 0.050; RR 4.9, CI 1.59-15.34, P = 0.005, respectively) ( Table 3) . When assessing the patients with very good partial response or better, the significance of abnormal HLC ratio was not as strong as for the entire group (RR 3.18, CI 0.84-12.04, P = 0.087).
DISCuSSIoN

Detection of monoclonal immunoglobulin
Using HLC assay, we successfully detected isotype and quantified monoclonal Ig in all multiple myeloma patients. HLC assay had greater sensitivity for monoclonal disease detection than total Ig result. It revealed an abnormal HLC ratio in almost half of the patients with total Ig levels within normal range, signifying the presence of monoclonal protein. Moreover, an abnormal HLC ratio was found in almost 20% of complete response patients, thus detecting the presence of residual disease when other laboratory techniques could not detect it. In support of this, 2 of the 5 patients in complete response but with an abnormal HLC ratio suffered relapse during the follow up period. Similar observations of abnormal HLC ratios in patients in complete response have been reported previously (18, 23) .
The HLC and serum FLC assays provided differing but complementary information. This was most apparent in patients in complete response: 4 patients had abnormal serum FLC ratio and normal HLC ratio, whereas 4 patients had the opposite results. Knowing the metabolism of FLC and intact Igs, one would expect that the normalization of the FLC ratio will precede or occur simultaneously with the normalization of HLC ratio. However, our data showed that normal HLC ratio values did not necessarily mean normal FLC ratio values or vice versa. Similar observations were reported previously (18) and are consistent with the two assays providing information on two independent markers of myeloma activity -the intact Igs and the FLC (24, 25) . These data suggest that both assays are required for the optimal follow-up of multiple myeloma patients. In support of this, when response of myeloma patients to treatment was assessed, it was shown that in patients achieving complete response or better, patients with abnormal both HLC and FLC ratio had a significantly shorter 2-year progression free survival (PFS) than those with either normal HLC or FLC ratio (26) .
Significance of the uninvolved hLC isotype pair suppression
Our results showing a strong association of suppression of the uninvolved HLC isotype pair with both markers of tumor burden (ie, FLC and hemoglobin) and shorter OS are particularly interesting. An analogous correlation of abnormal HLC ratios with shorter PFS in myeloma patients, particularly with more extreme HLC ratios, has been observed previously (27) . Interestingly, this association has been shown to be driven primarily and specifically by suppression of the uninvolved polyclonal HLC isotype pair, while suppression of the non-tumor Igs of different isotypes showed no significant correlation with PFS. Similarly, HLC pair suppression has been shown to be an additional independent risk factor for progression to malignancy in MGUS patients alongside serum monoclonal protein size, heavy chain isotype, and an abnormal serum FLC ratio (20) . The reason for the association of the outcome specifically with HLC pair-suppression in myeloma and MGUS remains unexplained. However, several studies in MGUS patients have noted higher levels of HLC pair suppression in IgG patients compared to IgA and IgM patients (20, 28) . An explanation for this is that due to relatively higher levels of background polyclonal IgG, which may help to prevent invasion of clonal plasma cells (29) hLC measurement values and impact on patients' outcome
Despite the fact that the data in this study were obtained from a heterogeneous group of multiple myeloma patients, we found a strong correlation between an abnormal HLC ratio and other markers of tumor burden (the percentage of clonal plasma cells in the bone marrow and an abnormal serum FLC ratio). Given the statistical strength of the correlation, one might expect this to impact the patient outcome. Indeed, patients with abnormal level of monoclonal HLC isotype or abnormal HLC ratio had significantly shorter OS than patients with normal monoclonal HLC isotype level or HLC ratio. In the group of patients who achieved very good partial response or better, HLC ratio value maintained its impact on patients' outcome while monoclonal HLC isotype concentrations above normal range did not.
Prognostic significance of the hLC measurements
In order to further assess the clinical relevance of HLC assay in the management of previously treated multiple myeloma patients, we additionally performed multivariate Cox regression analysis for the entire group as well as for patients in very good partial response or better. The analysis for the entire cohort confirmed the prognostic relevance of the HLC ratio along with high β2-microglobulin values.
Interestingly, the serum FLC ratio, which has been reported as predictive of outcome in several previous studies (32) (33) (34) (35) , was not significantly associated with OS in our study, most likely due to the fact that we did not include light chain multiple myeloma patients. The prognostic utility of HLC ratios in multiple myeloma using clinical presentation samples of untreated patients or patients recruited to clinical trials where all individuals received the same chemotherapeutic treatment followed by autologous stem cell transplantation (ASCT) treatment has recently been shown (18, 27) . However, in our study, patients were unselected and so were at different clinical stages of disease, received different chemotherapeutic regimes, and only a proportion had received ASCT treatment. Even in such a sample, we were able to evaluate the clinical utility of the HLC assay in everyday practice. Therefore, our finding that an abnormal HLC ratio, irrespective of disease stage and treatment regimen, is predictive of a poorer outcome in multiple myeloma is particularly noteworthy.
In conclusion, our results corroborate previous studies and show potential clinical utility of the HLC assay. In our study, the HLC ratio values correlated well with other prognostic tumor burden markers, showed enhanced sensitivity for the detection and quantification of monoclonal proteins, and affected patient outcome using a cohort of unselected patients in a daily practice setting. Interestingly, HLC pair suppression also correlated well with other tumor markers and was prognostic for shorter overall survival. Multivariate analysis confirmed an abnormal HLC ratio as an independent prognostic factor. Although larger studies using more defined groups of patients are required, our data suggest a clear role for HLC measurement in monitoring and response assessment of multiple myeloma patients with potential role in predicting patients' outcome. Declaration of authorship JB designed and supervised the study and wrote the manuscript. DN designed the study, performed patient follow-up, and reviewed the manuscript. ZP performed statistical analysis and reviewed the data. JL reviewed and revised the manuscript. SP, KD, DB, DSeg, LV, and DM performed the laboratory analysis. DSer, IR, SB-K performed patient follow-up and provided the clinical samples. BL reviewed the manuscript.
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